サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1362979

光線角化症治療市場規模、シェア、動向分析レポート：治療別、薬剤クラス別、最終用途別、地域別、セグメント別予測、2023年～2030年

Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy (Topical, Surgery, Photodynamic Therapy), By Drug Class, By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 170 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
光線角化症治療市場規模、シェア、動向分析レポート：治療別、薬剤クラス別、最終用途別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年09月12日
発行: Grand View Research
ページ情報: 英文 170 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

光線角化症治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の光線角化症治療市場規模は、2023年から2030年にかけてCAGR 4.3％を記録し、2030年までに89億米ドルに達する見込みです。

同市場は、光線角化症治療薬の幅広い入手可能性、同疾患に対する意識の高まり、AK治療の増加などの要因により、成長機会を目の当たりにすることが期待されます。さらに、光線角化症の有病率の増加や世界の老人人口の増加が、予測期間中の市場成長を促進すると予想されます。

浸潤性扁平上皮がんは、AKから悪性化すると発症する可能性があります（iSCC）。iSCCの潜在的な原因はいくつかあるが、AKは最も頻度の高い原因の1つです。さらに、基底細胞がんや非黒色腫皮膚がんもAKから発生する可能性があります。その結果、販売チャネルを問わずAK製品に対する需要は、合併症の予防戦略として、光線角化症の早期診断と治療が原動力となっています。

さらに、将来のパイプライン医薬品と併用療法の増加が市場促進要因となっています。例えば、Almirall, S.A.は、研究開発第III相段階にあるKlisyri（適応拡大）を有しています。さらに、革新的な医薬品が受け入れられ商品化されるようになったことも、市場成長を促進すると予測される要因のひとつです。さらに、研究開発活動の活発化により、光線角化症の治療に使用される新規薬剤の承認が加速されると予想されるため、予測期間中の成長が促進されます。

主要企業は、世界中で市場シェアを拡大するために、製品の発売、提携、拡大戦略などの戦略的イニシアチブを採用しています。例えば、2022年6月、BIOFRONTERA AGは、スイスに拠点を置くLouis Widmer SAが、Ameluzによる体幹、四肢、頸部の光線角化症の管理に関する販売承認の延長を受けたと発表しました。さらに、BIOFRONTERA AGは2020年7月、ノルウェー、フィンランド、ノルウェー、アイスランドにおけるBF-RhodoLEDおよびAmeluzの販売に関する契約をGalenica ABと締結したと発表しました。

光線角化症治療市場レポートハイライト

  • 2022年には、光線角化症の治療における凍結療法手術の採用が増加していることから、外科手術が65.6%の最大売上シェアを占めました。
  • ヌクレオシド代謝阻害剤は2022年に32.4%の最大収益シェアを占め、予測期間中もその優位性を維持すると予測されます。
  • アジア太平洋地域は、AKの有病率の高さ、急速に発展するヘルスケアインフラ、アジア太平洋諸国による医療費の増加などの要因により、予測期間中にCAGR 5.6%で最速の成長が見込まれています。
  • 北米は、光線角化症に対する人々の意識の高まり、強固な治療オプションの利用可能性、ヘルスケアインフラの改善などにより、2022年に41.5%の最大の売上シェアを獲得し、市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 光線角化症治療市場の変数、動向および範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 光線角化症治療市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 光線角化症治療市場：治療の推定・動向分析

  • 光線角化症治療市場：重要なポイント
  • 光線角化症治療市場：動向と市場シェア分析、2022年および2030年
  • 局所
  • 手術
  • 光線力学療法

第5章 光線角化症治療市場：薬剤クラスの推定・動向分析

  • 光線角化症治療市場：重要なポイント
  • 光線角化症治療市場：動向と市場シェア分析、2022年および2030年
  • ヌクレオシド代謝阻害剤
  • NSAIDS
  • 免疫応答修飾因子
  • フォトエンハンサー
  • その他

第6章 光線角化症治療市場：最終用途の推定・動向分析

  • 光線角化症治療市場：重要なポイント
  • 光線角化症治療市場：動向と市場シェア分析、2022年および2030年
  • 病院
  • プライベートクリニック
  • ホームケア
  • その他

第7章 光線角化症治療市場：地域の推定・動向分析

  • 地域別の展望
  • 地域別の日光角化症治療市場：重要なポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Almirall S.A.
    • LEO Pharma A/S
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • GALDERMA
    • Ortho Dermatologics (Bausch Health Companies Inc.)
    • BIOFRONTERA AG
    • Hill Dermaceuticals, Inc.
図表

List of Tables

  • 1. List of Abbreviations
  • 2. North America actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 3. North America actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 4. North America actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 5. North America actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • 6. U.S. actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 7. U.S. actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 8. U.S. actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 9. Canada actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 10. Canada actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 11. Canada actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 12. Europe actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 13. Europe actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 14. Europe actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 15. Europe actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • 16. Germany actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 17. Germany actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 18. Germany actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 19. UK actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 20. UK actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 21. UK actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 22. France actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 23. France actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 24. France actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 25. Italy actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 26. Italy actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 27. Italy actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 28. Spain actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 29. Spain actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 30. Spain actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 31. Sweden actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 32. Sweden actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 33. Sweden actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 34. Norway actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 35. Norway actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 36. Norway actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 37. Denmark actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 38. Denmark actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 39. Denmark actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 40. Asia Pacific actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 41. Asia Pacific actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 42. Asia Pacific actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 43. Asia Pacific actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • 44. China actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 45. China actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 46. China actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 47. Japan actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 48. Japan actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 49. Japan actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 50. India actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 51. India actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 52. India actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 53. Thailand actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 54. Thailand actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 55. Thailand actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 56. South Korea actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 57. South Korea actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 58. South Korea actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 59. Latin America actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 60. Latin America actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 61. Latin America actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 62. Latin America actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • 63. Brazil actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 64. Brazil actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 65. Brazil actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 66. Mexico actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 67. Mexico actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 68. Mexico actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 69. Argentina actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 70. Argentina actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 71. Argentina actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 72. Middle East and Africa actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 73. Middle East and Africa actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 74. Middle East and Africa actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 75. Middle East and Africa actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • 76. South Africa actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 77. South Africa actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 78. South Africa actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 79. Saudi Arabia actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 80. Saudi Arabia actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 81. Saudi Arabia actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 82. UAE actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 83. UAE actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 84. UAE actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 85. Kuwait actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 86. Kuwait actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 87. Kuwait actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • 1. Market research process
  • 2. Data triangulation techniques
  • 3. Primary research pattern
  • 4. Market research approaches
  • 5. Value-chain-based sizing & forecasting
  • 6. QFD modeling for market share assessment
  • 7. Market formulation & validation
  • 8. Actinic keratosis treatment: Market outlook
  • 9. Actinic keratosis treatment: Competitive insights
  • 10. Parent market outlook
  • 11. Related/ancillary market outlook
  • 12. Penetration and growth prospect mapping
  • 13. Industry value chain analysis
  • 14. Actinic keratosis treatment market driver impact
  • 15. Actinic keratosis treatment market restraint impact
  • 16. Actinic keratosis treatment market strategic initiatives analysis
  • 17. Actinic keratosis treatment market: Therapy movement analysis
  • 18. Actinic keratosis treatment market: Therapy outlook and key takeaways
  • 19. Topical market estimates and forecasts, 2018 - 2030 (USD Million)
  • 20. Surgery market estimates and forecasts, 2018 - 2030 (USD Million)
  • 21. Photodynamic therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 22. Actinic keratosis treatment market: Drug class movement analysis
  • 23. Actinic keratosis treatment market: Drug class outlook and key takeaways
  • 24. Nucleoside metabolic inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • 25. NSAIDS market estimates and forecasts, 2018 - 2030 (USD Million)
  • 26. Immune response modifiers market estimates and forecasts, 2018 - 2030 (USD Million)
  • 27. Photoenhancers market estimates and forecasts, 2018 - 2030 (USD Million)
  • 28. Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • 29. Actinic keratosis treatment market: End-use movement analysis
  • 30. Actinic keratosis treatment market: End-use outlook and key takeaways
  • 31. Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • 32. Private clinics delivery market estimates and forecasts, 2018 - 2030 (USD Million)
  • 33. Homecare market estimates and forecasts, 2018 - 2030 (USD Million)
  • 34. Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • 35. Global actinic keratosis treatment market: Regional movement analysis
  • 36. Global actinic keratosis treatment market: Regional outlook and key takeaways
  • 37. North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • 38. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • 39. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • 40. Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • 41. UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • 42. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • 43. France market estimates and forecasts, 2018 - 2030 (USD Million)
  • 44. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 45. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • 46. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • 47. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • 48. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • 49. Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • 50. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • 51. China market estimates and forecasts, 2018 - 2030 (USD Million)
  • 52. India market estimates and forecasts, 2018 - 2030 (USD Million)
  • 53. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 54. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • 55. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • 56. Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • 57. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • 58. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • 59. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • 60. Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • 61. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 62. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • 63. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • 64. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-2-68038-940-1

Actinic Keratosis Treatment Market Growth & Trends:

The global actinic keratosis treatment market size is expected to reach USD 8.9 billion by 2030, registering a CAGR of 4.3% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market is expected to witness growth opportunities owing to factors such as the wide availability of actinic keratosis therapeutics, rising awareness about the disease, and the rise in AK treatment. Moreover, the increasing prevalence of actinic keratosis and the rising geriatric population across the globe are expected to fuel the market growth during the forecast period.

Invasive squamous cell carcinoma may develop from AK when it becomes malignant (iSCC). Despite the fact that there are a number of potential causes for iSCC, AK is one of the most frequent ones. Additionally, basal cell carcinoma and non-melanoma skin cancer could result from AK. As a result, the demand for AK products across sales channels is being driven by the early diagnosis and treatment of actinic keratosis as a preventive strategy for comorbidities.

In addition, future pipeline medications and the increased use of combination therapy are key market drivers. For instance, Almirall, S.A. has Klisyri (extended label) in phase III of R&D. Furthermore, a rise in the acceptance and commercialization of innovative drugs is another factor that is predicted to fuel market growth. Moreover, increased R&D activities are expected to accelerate the approval of novel drugs used in the treatment of actinic keratosis, hence, propelling the growth over the forecast period.

Key players are adopting strategic initiatives such as product launches, partnerships, and expansion strategies to increase their market share across the globe. For instance, in June 2022, BIOFRONTERA AG announced that its license and marketing authorization holder Louis Widmer SA based in Switzerland has received an extension of its marketing authorization for the management of actinic keratosis in the trunk, extremities, and neck with Ameluz. Moreover, in July 2020, BIOFRONTERA AG announced that it has signed an agreement with Galenica AB for the marketing of BF-RhodoLED and Ameluz in Norway, Finland, Norway, and Iceland.

Actinic Keratosis Treatment Market Report Highlights:

  • Surgery held the largest revenue share of 65.6% in 2022 owing to the rising adoption of cryotherapy surgery in the management of actinic keratosis
  • Nucleoside metabolic inhibitors held the largest revenue share of 32.4% in 2022 and is expected to retain its dominance over the forecast period
  • Asia Pacific is expected to grow at the fastest CAGR of 5.6% during the forecast period due to factors such as the high prevalence of AK, rapidly evolving healthcare infrastructure, and rising healthcare expenditures by Asia Pacific countries
  • North America dominated the market with the largest revenue share of 41.5% in 2022 due to the rising awareness among people about actinic keratosis, availability of robust treatment options, and improvements in healthcare infrastructure

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Therapy
    • 1.1.2. Drug class
    • 1.1.3. End-use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Therapy outlook
    • 2.2.2. Drug class outlook
    • 2.2.3. End-use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Actinic Keratosis Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Actinic Keratosis Treatment Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Actinic Keratosis Treatment Market: Therapy Estimates & Trend Analysis

  • 4.1. Actinic Keratosis Treatment Market: Key Takeaways
  • 4.2. Actinic Keratosis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Topical
    • 4.3.1. Topical market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Surgery
    • 4.4.1. Surgery market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Photodynamic Therapy
    • 4.5.1. Photodynamic therapy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Actinic Keratosis Treatment Market: Drug Class Estimates & Trend Analysis

  • 5.1. Actinic Keratosis Treatment Market: Key Takeaways
  • 5.2. Actinic Keratosis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Nucleoside Metabolic Inhibitor
    • 5.3.1. Nucleoside metabolic inhibitor market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. NSAIDS
    • 5.4.1. NSAIDS market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Immune Response Modifiers
    • 5.5.1. Immune response modifiers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Photoenhancers
    • 5.6.1. Photoenhancers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Actinic Keratosis Treatment Market: End-use Estimates & Trend Analysis

  • 6.1. Actinic Keratosis Treatment Market: Key Takeaways
  • 6.2. Actinic Keratosis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Hospitals
    • 6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Private Clinics Delivery
    • 6.4.1. Private clinics delivery market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Homecare
    • 6.5.1. Homecare market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Actinic Keratosis Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Actinic Keratosis Treatment Market by Region: Key Takeaway
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Sweden
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Norway
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. Saudi Arabia
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. Almirall S.A.
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. LEO Pharma A/S
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Sun Pharmaceutical Industries Ltd.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Novartis AG
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. GALDERMA
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Ortho Dermatologics (Bausch Health Companies Inc.)
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. BIOFRONTERA AG
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Hill Dermaceuticals, Inc.
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives